MAP2K3 (Ab-222) Antibody

What is MAP2K3 and what biological pathways does it participate in?

Mitogen-activated protein kinase kinase 3 (MAP2K3), also known as dual specificity mitogen-activated protein kinase kinase 3 or MKK3, is a 39 kDa protein that functions as a critical component of the MAPK signaling pathway. MAP2K3 serves as a dual-specificity protein kinase that can phosphorylate both threonine and tyrosine residues in its target proteins .

MAP2K3 primarily functions as an activator of the p38-MAPK signaling pathway. When cells encounter external stimuli such as cellular stress, activated MAP3K phosphorylates and activates MAP2K3, which subsequently phosphorylates and activates the p38-MAPK pathway . This signaling cascade mediates cellular responses to various environmental changes and plays essential roles in inflammation, cell differentiation, and apoptosis.

In the signaling hierarchy, MAP2K3 operates downstream of MAP3K5/ASK1 (Apoptosis Signal-regulating Kinase 1), which is activated by various stressors including oxidative stress and inflammatory signals such as tumor necrosis factor (TNF) or lipopolysaccharide (LPS) . Once activated, MAP2K3 further propagates the signal by activating downstream p38 MAPKs that control transcription factors like activator protein-1 (AP-1) .

What are the key specifications of MAP2K3 (Ab-222) Antibody?

The MAP2K3 (Ab-222) Antibody is a rabbit polyclonal antibody specifically designed to detect endogenous levels of total MAP2K3 protein . This antibody was generated using a synthesized non-phosphopeptide derived from human MAP2K3 around the phosphorylation site of threonine 222 (A-K-T(p)-M-D) . The antibody has been affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen .

Key specifications include:

• Host Species: Rabbit

• Clonality: Polyclonal

• Species Reactivity: Human , with some products also tested in mouse models

• Applications: Western Blot (WB), Immunofluorescence (IF), and ELISA

• Concentration: 1.0mg/ml

• Molecular Weight: 39kDa by SDS-PAGE

• Target Protein Details: Swiss-Prot accession P46734, NCBI Gene ID 5606

The antibody is supplied in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, containing 150mM NaCl, 0.02% sodium azide, and 50% glycerol .

What are the validated applications for MAP2K3 (Ab-222) Antibody?

The MAP2K3 (Ab-222) Antibody has been validated for multiple experimental applications, making it versatile for various research protocols:

The antibody has been successfully tested in human cell lines, with Jurkat cells (treated with 20% serum for 15 minutes) being specifically documented in Western blot applications . When designing experiments, researchers should consider performing preliminary titration experiments to determine optimal antibody concentrations for their specific experimental setup.

What are the recommended storage and handling conditions?

For optimal performance and longevity, MAP2K3 (Ab-222) Antibody should be stored at -20°C . Some suppliers may also recommend storage at -80°C for long-term preservation .

When handling the antibody:

• Avoid repeated freeze-thaw cycles as this can degrade the antibody

• Aliquot the antibody upon receipt for long-term storage

• Bring to room temperature before use

• Centrifuge briefly before opening the vial to collect contents

• If dilution is necessary, use fresh, sterile buffers

The antibody is formulated in phosphate buffered saline with glycerol (50%) and sodium azide (0.02%) as preservatives . These components help maintain stability during storage, but users should be aware that sodium azide is toxic and should be handled with appropriate safety precautions.

How can researchers optimize Western blot protocols using MAP2K3 (Ab-222) Antibody?

When optimizing Western blot protocols with MAP2K3 (Ab-222) Antibody, researchers should consider several critical parameters:

Sample Preparation:

• Cell stimulation conditions significantly impact detection. For example, serum treatment (20%, 15 minutes) of Jurkat cells has been validated for successful detection

• Include both positive controls (cells known to express MAP2K3) and negative controls

• Use phosphatase inhibitors in lysis buffers if studying phosphorylation status

• Standardize protein quantification methods for consistent loading

Electrophoresis and Transfer:

• Use 10-12% polyacrylamide gels for optimal resolution of the 39kDa MAP2K3 protein

• Consider using PVDF membranes over nitrocellulose for phospho-specific applications

• Wet transfer methods may provide better results than semi-dry for this antibody

Antibody Incubation:

• Recommend starting dilutions: 1:500 to 1:1000

• Incubate primary antibody at 4°C overnight for maximum sensitivity

• Use 5% BSA in TBST for blocking and antibody dilution, especially for phospho-detection

• Include extensive washing steps (at least 3×10 minutes) between antibody incubations

Signal Development:

• Enhanced chemiluminescence (ECL) detection systems are suitable

• Consider using digital imaging systems for quantitative analysis

• For multiplex detection, use secondary antibodies with distinct fluorophores

When troubleshooting, non-specific bands may appear if blocking is insufficient or if the antibody concentration is too high. Increasing blocking time or adjusting antibody dilution can often resolve these issues.

What methodological approaches can researchers use to study MAP2K3's role in cancer, particularly glioma?

Recent research has identified MAP2K3 as a potential prognostic biomarker and immunotherapy target in glioma treatment . Researchers investigating MAP2K3's role in cancer can employ several methodological approaches:

Expression Analysis:

• Use Western blot with MAP2K3 (Ab-222) Antibody to compare expression levels between tumor and normal tissue samples

• Perform immunohistochemistry on patient-derived tissue microarrays to correlate expression with clinical outcomes

• Analyze public gene expression databases to validate findings across larger cohorts

Functional Studies:

• Use siRNA or CRISPR-Cas9 to knock down/out MAP2K3 in glioma cell lines

• Assess effects on proliferation, migration, invasion, and apoptosis

• Analyze downstream p38-MAPK pathway activation using phospho-specific antibodies

• Combine MAP2K3 targeting with immune checkpoint inhibitors to test synergistic effects

Biomarker Development:

• Correlate MAP2K3 expression with patient survival data and treatment response

• Develop standardized scoring systems for immunohistochemistry

• Validate cutoff values for "high" versus "low" expression in multiple cohorts

Studies have shown that MAP2K3 influences the tumor immune microenvironment through regulation of immune cell infiltration, which has significant implications for immunotherapy approaches in glioma . When designing studies to explore MAP2K3 as an immunotherapy target, researchers should incorporate immune cell profiling using techniques such as multiplex immunofluorescence or flow cytometry to characterize the immune landscape before and after MAP2K3 modulation.

How does MAP2K3 interact with the ASK1-p38 MAPK pathway in stress response?

MAP2K3 functions as a critical intermediary in the ASK1-p38 MAPK signaling cascade. Understanding this relationship requires specific experimental approaches:

• ASK1 (MAP3K5) is activated by various stressors including oxidative stress and inflammatory signals such as TNF or LPS

• Once activated, ASK1 phosphorylates and activates several MAP kinase kinases including MAP2K3/MKK3

• MAP2K3 then phosphorylates and activates p38 MAPK, which controls transcription factors like AP-1

To study this pathway interaction experimentally:

Co-immunoprecipitation Studies:

• Use MAP2K3 (Ab-222) Antibody to immunoprecipitate MAP2K3 and probe for interaction with ASK1

• Reverse IP with ASK1 antibody to confirm interaction

Phosphorylation Analysis:

• Examine the phosphorylation status of MAP2K3 at threonine 222 after ASK1 activation

• Monitor activation of downstream p38 MAPK

• Use phospho-specific antibodies in conjunction with total protein antibodies

Stress Response Analysis:

• Compare cellular responses to stressors (oxidative stress, cytokines) in cells with normal MAP2K3 versus knockdown

• Measure endpoints such as cell viability, apoptosis markers, and inflammatory mediators

Inhibitor Studies:

• Use ASK1 inhibitors to block upstream activation

• Measure effects on MAP2K3 phosphorylation and function

• Compare with direct p38 MAPK inhibitors to distinguish pathway-specific effects

What are the critical controls needed when using MAP2K3 (Ab-222) Antibody in immunofluorescence experiments?

When conducting immunofluorescence (IF) experiments with MAP2K3 (Ab-222) Antibody, researchers must include several critical controls:

Primary Controls:

• Positive Control: Include cells/tissues known to express MAP2K3

• Negative Control: Include cells with verified low/no MAP2K3 expression or MAP2K3 knockout models

• Primary Antibody Omission: Process samples without primary antibody to assess secondary antibody specificity

• Isotype Control: Use matched concentration of irrelevant rabbit IgG to evaluate non-specific binding

• Peptide Blocking: Pre-incubate antibody with immunizing peptide to confirm specificity

Experimental Controls:

• Subcellular Localization Markers: Include markers for cellular compartments (nucleus, cytoplasm, etc.)

• Pathway Activation Controls: Compare samples with and without stimuli known to activate the MAP2K3 pathway

• Phosphorylation Controls: If studying activation, include phosphatase-treated samples

Technical Considerations:

• Start with 1:50 to 1:200 dilutions for immunofluorescence applications

• Use 4% paraformaldehyde fixation (10-15 minutes) followed by 0.1% Triton X-100 permeabilization

• Block with 5% normal serum from the species of secondary antibody

• Counterstain nuclei with DAPI

• Minimize exposure to light after secondary antibody application

Careful image acquisition and analysis are essential for accurate interpretation of results. Use the same exposure settings across all samples and include scale bars in all images.

How can researchers validate MAP2K3 as a prognostic biomarker in cancer studies?

Validating MAP2K3 as a prognostic biomarker in cancer research requires a systematic approach:

Discovery Phase:

• Use MAP2K3 (Ab-222) Antibody in tissue microarrays to assess expression across tumor samples

• Correlate expression with clinical outcomes (survival, recurrence, treatment response)

• Determine optimal scoring methods and cutoff values

Validation Phase:

• Confirm findings in independent cohorts

• Perform multivariate analysis to assess independence from established prognostic factors

• Validate using alternative detection methods (qPCR, mass spectrometry)

Mechanistic Studies:

• Investigate the biological basis of MAP2K3's prognostic significance

• Examine relationships with immune cell infiltration in tumor microenvironment

• Assess impact on cancer hallmarks (proliferation, invasion, etc.)

For glioma specifically, recent research has indicated that unconventional levels of MAP2K3 gene expression correlate with malignancy and immune cell infiltration . The approach should include analysis of MAP2K3 expression in relation to:

When conducting these studies, researchers must ensure standardized sample collection, processing, and scoring to maximize reproducibility across institutions.

What are common issues encountered with MAP2K3 (Ab-222) Antibody and how can they be resolved?

Researchers may encounter several technical challenges when using MAP2K3 (Ab-222) Antibody:

Weak or No Signal:

• Potential Causes: Insufficient antibody concentration, protein degradation, low target expression

• Solutions:

  • Increase antibody concentration

  • Increase protein loading amounts

  • Use fresh lysates with added protease inhibitors

  • Extend primary antibody incubation time

  • Verify MAP2K3 expression in chosen cell type

Multiple Bands in Western Blot:

• Potential Causes: Cross-reactivity, protein degradation, post-translational modifications

• Solutions:

  • Increase blocking time and washing steps

  • Optimize antibody dilution

  • Include phosphatase inhibitors if studying phosphorylated forms

  • Use freshly prepared samples

  • Run gradient gels for better resolution

High Background in Immunofluorescence:

• Potential Causes: Insufficient blocking, antibody concentration too high, inadequate washing

• Solutions:

  • Increase blocking time (2 hours at room temperature)

  • Use higher concentration of blocking agent (5-10% normal serum)

  • Extend washing steps (4-5 times, 5 minutes each)

  • Further dilute primary and secondary antibodies

  • Include 0.1% Tween-20 in wash buffer

Inconsistent Results Across Experiments:

• Potential Causes: Variation in sample preparation, antibody storage issues, protocol inconsistencies

• Solutions:

  • Standardize all protocol steps

  • Aliquot antibody to avoid freeze-thaw cycles

  • Use internal loading controls

  • Process all comparative samples simultaneously

How can researchers distinguish between total and phosphorylated MAP2K3 in experimental designs?

Distinguishing between total and phosphorylated MAP2K3 is critical for pathway activation studies. The MAP2K3 (Ab-222) Antibody specifically recognizes total MAP2K3 protein regardless of phosphorylation status, as it was generated using a non-phosphopeptide around the phosphorylation site of threonine 222 .

Experimental Approach:

• Parallel Detection: Use separate phospho-specific and total MAP2K3 antibodies on duplicate blots

• Sequential Detection: Strip and reprobe membranes with alternative antibody (total or phospho-specific)

• Ratio Analysis: Calculate phospho/total ratios to normalize for expression differences

Technical Considerations:

• Always detect phosphorylated forms first when stripping and reprobing

• Use phosphatase inhibitors in lysis buffers

• Avoid heat-based sample preparation when studying phosphorylation

• Consider using phosphatase treatment as negative control

Advanced Applications:

• Kinase Assays: Use recombinant p38 MAPK as substrate to measure MAP2K3 activity

• Proximity Ligation Assays: Detect phosphorylated MAP2K3 in situ with high sensitivity

• Flow Cytometry: Quantify phosphorylated versus total MAP2K3 at single-cell level

When interpreting results, remember that phosphorylation at different sites may have distinct functional consequences, and that temporal dynamics of phosphorylation are often critical for understanding signaling events.

How can MAP2K3 (Ab-222) Antibody be used to investigate immunotherapy strategies?

MAP2K3 has emerged as a potential immunotherapy target, particularly in glioma treatment . Researchers can use MAP2K3 (Ab-222) Antibody to investigate immunotherapy strategies through several approaches:

Tumor Microenvironment Analysis:

• Use immunofluorescence to co-localize MAP2K3 with immune cell markers in tumor sections

• Quantify relationships between MAP2K3 expression and infiltrating immune cell populations

• Assess correlation between MAP2K3 levels and immune checkpoint molecule expression

Therapeutic Target Validation:

• Use MAP2K3 (Ab-222) Antibody to monitor protein levels following genetic or pharmacological inhibition

• Analyze effects on downstream signaling pathways

• Correlate MAP2K3 inhibition with changes in immune cell function and tumor response

Combination Therapy Assessment:

• Evaluate MAP2K3 expression before and after immune checkpoint inhibitor treatment

• Test combination approaches targeting both MAP2K3 and immune checkpoints

• Monitor changes in tumor infiltrating lymphocytes following combination treatments

In glioma models specifically, where MAP2K3 has been identified as a potential prognostic biomarker , researchers could develop experimental designs to:

• Compare MAP2K3 expression between responders and non-responders to immunotherapy

• Develop MAP2K3-based patient stratification strategies

• Target MAP2K3 to potentially enhance response to existing immunotherapies

What methodological approaches can be used to study MAP2K3's role in inflammatory pathways?

MAP2K3 plays a critical role in inflammatory signal transduction as part of the p38 MAPK pathway. Researchers can employ several methodological approaches using MAP2K3 (Ab-222) Antibody:

Cellular Activation Studies:

• Stimulate cells with inflammatory mediators (LPS, TNF-α, IL-1β)

• Monitor MAP2K3 expression and phosphorylation status over time

• Correlate with downstream inflammatory marker expression

Genetic Modulation:

• Use siRNA or CRISPR-Cas9 to knockdown/knockout MAP2K3

• Overexpress wild-type or mutant MAP2K3

• Assess effects on inflammatory response using cytokine arrays or multiplex assays

Pharmacological Intervention:

• Treat cells with p38 MAPK pathway inhibitors

• Monitor effects on MAP2K3 expression and activity

• Combine with inflammatory stimuli to assess pathway modulation

Ex Vivo Analysis:

• Isolate primary cells from inflammatory disease models

• Compare MAP2K3 expression and activation status with healthy controls

• Correlate with disease severity and treatment response

When designing these studies, researchers should consider that MAP2K3 function may be cell type-specific and context-dependent. Including multiple cell types and stimulation conditions will provide a more comprehensive understanding of MAP2K3's role in inflammatory processes.